/

Binaytara Foundation Hosted Seattle Cellular Therapy Summit

1 min read

Hematologists & Oncologists from Across Country Met to Discuss Latest Updates in Care

 

On August 4-5, 2023, the Binaytara Foundation held the Seattle Cellular Therapy Summit. This annual conference gathers leading experts to present the latest treatments and practice-changing updates in care.

 

Drs. Mazyar Shadman and Krish Patel, of the University of Washington/Fred Hutchinson and Swedish Cancer Institute, respectively, led the meeting, providing practice-changing information to around 100 attendees. Session topics included Updates on Approved CAR-T Cell Therapies, Addressing Barriers to Cellular Therapy, and Debates on Myeloma & MCL.

“Dr. Shadman, Dr. Shah, and I, with the help of the Foundation, put together this meeting with wonderful faculty experts from around the country who are the leaders in cellular therapy. We are thrilled to have this inaugural conference in Seattle, and we hope for this conference to be an annual meeting. It’s been a joy to work with the Binaytara Foundation towards this goal.” Dr. Patel explained.

 

The meeting featured faculty from City of Hope, Moffitt Cancer Center, University of Washington, Fred Hutch, Providence, University of Nebraska, Mayo Clinic, and MD Anderson Cancer Center.

 

“This meeting has brought together experts from across the country interested in adaptive cellular immunotherapies. I am very impressed with what the Foundation is doing in global health, understanding disparities, and advancing education in cancer care across the spectrum. I am thrilled to be here. It was lovely to see the perspectives, debates, and interactions among faculty today discussing cutting-edge adaptive T-cell therapies, including CAR-T therapies.” Dr. Krishna Komanduri, Dr. Krishna Komanduri, Physician in-chief at the UCSF Hellen Diller Family Comprehensive Cancer Center, shared.

 

We thank the conference co-chairs, faculty, BTF staff, and volunteers for an amazing conference. We look forward to next year!

Latest from Blog

HER2CLIMB-02

By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center   Tucatinib, a HER2-directed tyrosine kinase

INAVO120 trial

By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center   Development of endocrine resistance remains